Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders
Molecular Pharmacology · 2024-05 · 105 (5) · 348-358
DOI: 10.1124/molpharm.124.000874 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmacology, 2024-05. Verfasst von Harrison H Parent und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology (H.H.P., C.M.N.), Warren Center for Neuroscience Drug Discovery (H.H.P., C.M.N.), Vanderbilt Brain Institute (C.M.N.), and…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Receptors, Metabotropic Glutamate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NINDS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Metabotropic glutamate receptor 7 (mGlu7) is the most highly conserved and abundantly expressed mGlu receptor in the human brain. The presynaptic localization of mGlu7, coupled with its low affinity for its endogenous agonist, glutamate, are features that contribute to the receptor's role in modulating neuronal excitation and inhibition patterns, including long-term potentiation, in various brain regions. These characteristics suggest that mGlu7 modulation may serve as a novel therapeutic strategy in disorders of cognitive dysfunction, including neurodevelopmental disorders that cause impairments in learning, memory, and attention. Primary mutations in the GRM7 gene have recently been identified as novel causes of neurodevelopmental disorders, and these patients exhibit profound intellectual and cognitive disability. Pharmacological tools, such as agonists, antagonists, and allosteric modulators, have been the mainstay for targeting mGlu7 in its endogenous homodimeric form to probe effects of its function and modulation in disease models. However, recent research has identified diversity in dimerization, as well as trans-synaptic interacting proteins, that also play a role in mGlu7 signaling and pharmacological properties. These novel findings represent exciting opportunities in the field of mGlu receptor drug discovery and highlight the importance of further understanding the functions of mGlu7 in complex neurologic conditions at both the molecular and physiologic levels. SIGNIFICANCE STATEMENT: Proper expression and function of mGlu7 is essential for learning, attention, and memory formation at the molecular level within neural circuits. The pharmacological targeting of mGlu7 is undergoing a paradigm shift by incorporating an understanding of receptor interaction with other cis- and trans- acting synaptic proteins, as well as various intracellular signaling pathways. Based upon these new findings, mGlu7's potential as a drug target in the treatment of cognitive disorders and learning impairments is primed for exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology (H.H.P., C.M.N.), Warren Center for Neuroscience Drug Discovery (H.H.P., C.M.N.), Vanderbilt Brain Institute (C.M.N.), and Vanderbilt Institute for Chemical Biology (C.M.N.), Vanderbilt Univer…
ORCID-Profile: Harrison H Parent, Colleen M Niswender
Förderung
- NIMH NIH HHS
- NINDS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Parent, H. H., & Niswender, C. M. (2024). Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders. Molecular Pharmacology, 105(5), 348-358. https://doi.org/10.1124/molpharm.124.000874
Vancouver
Parent HH, Niswender CM. Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders. Molecular Pharmacology. 2024;105(5):348-358. doi:10.1124/molpharm.124.000874
BibTeX
@article{Parent2024,
author = {Parent, Harrison H and Niswender, Colleen M},
title = {Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders},
journal = {Molecular Pharmacology},
year = {2024},
volume = {105},
number = {5},
pages = {348--358},
doi = {10.1124/molpharm.124.000874}
}
EUVIMED